Messung von Plasmakonzentrationen antiretroviraler Arzneimittel in der HIV-Therapie

Schlüsselwörter

Plasmakonzentration - antiretrovirale Arzneimittel - HIV-Therapie - therapeutisches „Drug monitoring”

Key words

plasma concentration - antiretrovirals - HIV-therapy - therapeutic drug monitoring

Literatur

• 1 Aptivus. Prescribing Information. Boehringer Ingelheim International GmbH Ingelheim, Germany 10 003 515/US/1, Issued June 23 2005
• 2 Department of Health and Human Services .Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - October 10, 2006, updated February 2007. www.aidsinfo.nih.gov, accessed 13 052007
• 3 Department of Health and Human Services .Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States July 6, 2006. www.aidsinfo.nih.gov, assessed Sept 2006
• 4 http://medicine.iupui.edu/flockhart/table.htm. accessed. 10.11.2006
• 5 Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs.  Ther Drug Monit. 2006;  28 468-473
• 6 Boffito M, Kurowski M, Kruse G, Hill A, Benzie A, Nelson M, Moyle G, Gazzard B, Pozniak A. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir boosted once-daily regimen.  AIDS. 2004;  18 1291-1297
• 7 Bossi P, Peytavin G, Ait-Mohand H. et al . GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.  HIV Med. 2004;  5 352-359
• 8 Breilh D, Pellegrin I, Rouzes A. et al . Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).  AIDS. 2004;  18 1305-1310
• 9 Brundage R C, Yong Y H, Fenton T, Spector S A, Starr S E, Fletcher C V. Intrapatient variability of efavirenz concentrations as a predictor of virologicresponse to antiretroviral therapy.  Antimicrob Agents Chemother. 2004;  48 979-984
• 10 Burger D, Hugen P, Reiss P. et al . Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.  AIDS. 2003;  17 1157-1165
• 11 Burger D, van Rossum A, Hugen P. et al . Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.  Antimicrob Agents Chemother. 2001;  45 701-705
• 12 Sustiva product information. Bristol Myers Squibb Princeton, 08543 NJ, USA T4-B0001 - 04 - 05/Revised, issued 2005
• 13 Crommentuyn K, Scherpbier H, Kuijpers T, Mathot R, Huitema A, Beijnen J. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.  Pediatr Infect Dis J. 2006;  25 538-543
• 14 Eron J, Feinberg J, Kessler H. et al . Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV-positive patients: a 48-week randomized clinical trial.  J Infect Dis. 2004;  189 265-272
• 15 Fang C T, Chang Y Y, Hsu H M. et al . Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.  Qjm. 2007;  100 97-105
• 16 Fellay J, Marzolini C, Meaden E, Back D, Buclin T, Chave J. et al . Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1.  Lancet. 2002;  359 30-36
• 17 Fletcher C, Anderson P, Kakuda T, Schacker T, Henry K, Gross C, Brundage R. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.  AIDS. 2002;  16 551-560
• 18 de Gonzalez R equena DBS, Garazzino S, Sciandra M. et al . Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.  Antimicrob Agents Chemother. 2005;  49 3966-3969
• 19 Haas D W, Smeaton L M, Shafer R W. et al . Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir.  J Infect Dis. 2005;  192 1931-1942
• 20 Hayashi S, Beckerman K, Homma M, Kosel B, Aweeka F. Pharmacokinetics of indinavir in HIV-positive pregnant women.  AIDS. 2000;  14 1061-1062
• 21 Hirt D, Treluyer J, Jullien V. et al . Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.  Antimicrob Agents Chemother. 2006a;  50 2079-2086
• 22 Hirt D, Urien S, Jullien V. et al . Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.  Antimicrob Agents Chemother. 2006b;  50 910-916
• 23 Huang Y, Liu D, Wu H. Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system.  Biometrics. 2006;  62 413-423
• 24 Johnson M, Gathe J J, Podzamczer D. et al . A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen.  J Acquir Immune Defic Syndr. 2006; [Epub ahead of print]; 
• 25 Johnson M, Grinsztejn, B, Rodriguez C. et al . Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.  AIDS. 2005;  19 685-694
• 26 Kappelhoff B S, van Leth F, MacGregor T R, Lange J, Beijnen J H, Huitema A D. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.  Antivir Ther. 2005;  10 145-155
• 27 Kashuba A. Drug-drug interactions and the pharmacotherapy of HIV infection.  Top HIV Med. 2005;  13 64-69
• 28 Kosel B, Beckerman K, Hayashi S, Homma M, Aweeka F. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.  AIDS. 2003;  17 1195-1199
• 29 la P orte C, Back D, Blaschke T. et al . Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents.  Reviews in Antiviral Therapy. 2006;  3 3-14
• 30 Lima V D, Hogg R S, Harrigan P R. et al . Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.  AIDS. 2007;  21 685-692
• 31 Marzolini C TA, Decosterd L A, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.  AIDS. 2001;  15 71-75
• 32 Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women.  Clin Pharmacokinet. 2004;  43 1071-1087
• 33 Ren Y, Nuttall J, Egbers C. et al . High prevalence of subtherapeutic plasma concentrations of efavirenz in children.  J Acquir Immune Defic Syndr. 2007;  45 133-136
• 34 Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P. et al . Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.  AIDS. 2007;  21 41-46
• 35 Rosso R, Di Biagio A, Dentone C. et al . Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.  J Antimicrob Chemother. 2006;  57 1168-1171
• 36 Sension M G. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.  J Assoc Nurses AIDS Care. 2007;  18 S2-10
• 37 Stek A M, Mirochnick M, Capparelli E. et al . Reduced lopinavir exposure during pregnancy.  AIDS. 2006;  20 1931-1939
• 38 Verweel G, Burger D M, Sheehan N L. et al . Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.  Antivir Ther. 2007;  12 453-458
• 39 von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr H, Lötsch J. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pretreated patients in clinical practice.  Antivir Ther. 2007a;  12 1237-46
• 40 von Hentig N, Carlebach A, Gute P. et al . A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.  Br J Clin Pharmacol. 2006a;  62 552-559
• 41 von Hentig N, Carlebach A, Gute P. et al . A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.  Br J Clin Pharmacol. 2006b;  62 552-559
• 42 von Hentig N, Koenigs C, Elanjikal S. et al . Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.  Eur J Med Res. 2006c;  11 377-380
• 43 von Hentig N, Muller A, Rottmann C. et al . Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.  Eur J Med Res. 2006d;  11 236-244
• 44 von Hentig N, Muller A, Rottmann C. et al . Pharmacokinetics of saquinavir, atazanavir and ritonavir in a boosted double-protease inhibitor twice-daily regimen.  Antimicrobial Agents and Chemotherapy. 2006d; accepted 12.12.2006; 
• 45 von Hentig N, Muller A, Rottmann C. et al . Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.  Antimicrob Agents Chemother. 2007b;  51 1431-1439
• 46 Zhang X, Lin T, Bertasso A. et al . Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.  J Clin Pharmacol. 2007;  47 510-517